从 196 7年急性呼吸窘迫综合征(ARDS)命名以来 ,诊断方法和界定标准已经取得共识 ,理论研究非常活跃。尽管各种疗法不断出现 ,但疗效满意 ,操作简单方便 ,费用经济 ,易于为临床医生和患者接受的药理学方法却寥然无几〔1〕。1995年我们在庐山“95全国危重病急救医学学术会议”上 Since the designation of acute respiratory distress syndrome (ARDS) in 1977, consensus has been reached on diagnostic methods and criteria, and theoretical studies have been very active. Although a variety of therapies continue to emerge, their efficacy is satisfactory, they are easy to operate and cost-effective, and their pharmacology, which is readily available to clinicians and patients, is scarce [1]. In 1995 we Lushan “95 National Critical Care Medicine Symposium” on